J Korean Med Sci.  2020 Apr;35(15):e154. 10.3346/jkms.2020.35.e154.

Walk-Through Screening Center for COVID-19: an Accessible and Efficient Screening System in a Pandemic Situation

• Kim SI
• Lee JY

• KMID: 2500196
• DOI: http://doi.org/10.3346/jkms.2020.35.e154

Abstract

With the ongoing novel coronavirus disease 2019 (COVID-19) pandemic, the number of individuals that need to be tested for COVID-19 has been rapidly increasing. A walk-through (WT) screening center using negative pressure booths that is inspired by the biosafety cabinet has been designed and implemented in Korea for easy screening of COVID-19 and for safe and efficient consultation for patients with fever or respiratory symptoms. Here, we present the overall concept, advantages, and limitations of the COVID-19 WT screening center. The WT center increases patient access to the screening clinics and adequately protects healthcare personnel while reducing the consumption of personal protective equipment. It can also increase the number of people tested by 9–10 fold. However, there is a risk of cross-infection at each stage of screening treatment, including the booths, and adverse reactions with disinfection of the booths. These limitations can be overcome using mobile technology and increasing the number of booths to reduce congestion inside the center, reducing booth volume for sufficient and rapid ventilation, and using an effective, harmless, and certified environmental disinfectant. A WT center can be implemented in other institutions and countries and modified depending on local needs to cope with the COVID-19 pandemic.

Keyword

Walk-through; Screening; SARS-CoV-2; COVID-19; Pandemic

Figure

• 

  Fig. 1 Schematic blueprint of Safe Assessment and Fast Evaluation Technical booth of the H Plus Yangji Hospital.

• 

  Fig. 2 Picture of Safe Assessment and Fast Evaluation Technical booth of the H Plus Yangji Hospital. The height of the glove hole in all booths is different.

• 

  Fig. 3 Flowchart of a walk-through screening center.

Reference

1. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report – 56. Updated 2020. Accessed March 16, 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200316-sitrep-56-covid-19.pdf?sfvrsn=9fda7db2_6.

2. Kwon KT, Ko JH, Shin H, Sung M, Kim JY. Drive-through screening center for COVID-19: a safe and efficient screening system against massive community outbreak. J Korean Med Sci. 2020; 35(11):e123. PMID: 32193904.

3. Korea Statistics. Population census. Updated 2020. Accessed April 2, 2020. http://kosis.kr/statisticsList/statisticsListIndex.do?menuId=M_01_01&vwcd=MT_ZTITLE&parmTabId=M_01_01#SelectStatsBoxDiv.

4. Jensen PA, Lambert LA, Iademarco MF, Ridzon R; CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep. 2005; 54(RR-17):1–141.

5. Centers for Disease Control and Prevention. Interim infection prevention and control recommendations for patients with suspected or confirmed coronavirus disease 2019 (COVID-19) in healthcare settings. Updated 2020. Accessed March 23, 2020. https://www.cdc.gov/coronavirus/2019-ncov/infection-control/control-recommendations.html.

6. World Health Organization. Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected. Interim guidance. Updated 2020. Accessed March 25, 2020. https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125.

7. Centers for Disease Control and Prevention. Updated 2020. Accessed March 20, 2020. http://ncov.mohw.go.kr/searchBoardView.do?brdId=2&brdGubun=25&dataGubun=&ncvContSeq=1085.

8. Centers for Disease Control and Prevention. Updated 2020. Accessed March 25, 2020. https://www.cdc.go.kr/board/board.es?mid=a20507020000&bid=0019.

9. United states Environmental Protection Agency. List N: disinfectants for use against SARS-CoV-2. Updated 2020. Accessed March 24, 2020. https://www.epa.gov/pesticide-registration/list-n-disinfectants-use-against-sars-cov-2.

10. Oxivir® Tb RTU. Accessed March 22, 2020. http://solutionsdesignedforhealthcare.com/solutions/products/disinfectants/oxivir-tb-rtu.

11. Chartier Y, Pessoa-Silva C. Natural Ventilation for Infection Control in Health-care Settings. Geneva: World Health Organization;2009.